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Abstract
Despite mortality due to communicable diseases, poverty, and human conflicts, dementia
incidence is destined to increase in the developing world in tandem with the ageing population.
Current data from developing countries suggest that age-adjusted dementia prevalence estimates in
65 year olds are high (≥5%) in certain Asian and Latin American countries, but consistently low
(1–3%) in India and sub-Saharan Africa; Alzheimer's disease accounts for 60% whereas vascular
dementia accounts for ∼30% of the prevalence. Early-onset familial forms of dementia with
single-gene defects occur in Latin America, Asia, and Africa. Illiteracy remains a risk factor for
dementia. The APOE ε4 allele does not influence dementia progression in sub-Saharan Africans.
Vascular factors, such as hypertension and type 2 diabetes, are likely to increase the burden of
dementia. Use of traditional diets and medicinal plant extracts might aid prevention and treatment.
Dementia costs in developing countries are estimated to be US$73 billion yearly, but care
demands social protection, which seems scarce in these regions.
Introduction
Older people with dementia exist in nearly every country in the world. Dementia rates are
predicted to increase at an alarming rate in the least developed and developing regions of the
world despite mortality resulting from malnutrition, poverty, war, and infectious diseases.
WHO projections suggest that by 2025, about three-quarters of the estimated 1.2 billion
people aged 60 years and older will reside in developing countries.1 Thus, by 2040, if
growth in the older population continues, and there are no changes in mortality or burden
reduction by preventive measures, 71% of 81.1 million dementia cases will be in the
developing world.2 About 4.6 million new cases of dementia are added every year, with the
highest growth projections in China and its south Asian neighbours. These projections might
be confounded by temporal changes due to shorter survival after dementia,3 lack of
education and awareness, inadequate diagnostic assessment,4 and variability in costs of care
of the elderly with dementia,5 all of which could lead to under-accounting of the dementia
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burden.6 In China, for example, 49% of patients with dementia were classified as normally
ageing and only 21% had adequate access to diagnostic assessment,7 compared with 20%
and more than 70%, respectively, in Europe.8
There are no known curative or preventive measures for most types of dementia. Diet and
lifestyle could influence risk, and studies suggest that midlife history of disorders that affect
the vascular system, such as hypertension, type 2 diabetes, and obesity, increase the risk for
dementia including Alzheimer's disease (AD).9–12 Increased trends in demographic
transition and urbanisation within many developing countries are predicted to lead to
lifestyle changes.13 Delaying of onset, by modifying risk or lifestyle, decreases the
prevalence and public health burden of dementia; a delay in onset of 1 year would translate
to almost a million fewer prevalent cases in the USA.14 However, this in turn might increase
demands on health services and costs for older populations.15
We review published prevalence estimates and modifying factors for brain ageing-related
dementias in developing regions of the world, as defined by the United Nations.16 Our
report is limited to ageing-related neurodegenerative and vascular dementias and does not
address dementia secondary to retroviruses (eg, HIV) or other infectious agents, recognising
that these might assume importance in younger adults or in specific regions. Other reviews
have focussed on these issues,15,17,18 but we take particular note of genetic and
environmental factors,18,19 in addition to the problems encountered in accounting for
differences in dementia occurrence between developed and developing countries. Although
more data from developing countries are needed, several comparative dementia prevalence
and risk-factor assessment projects, which use similar designs, survey methods, and
investigators, have been invaluable resources to allow examination of phenotypic variations
in dementias in populations living in very different cultures and environments.18,20–22
Dementia screening
Neuropsychometric assessment seems to be the best method to screen individuals in most
developing countries.23 At the outset, the lack of standardisation of screening tools has to be
recognised as a major issue in the estimation of the true burden.20 Standardisation might not
be readily achieved because of diversity of language, culture, and levels of literacy. In
certain communities, more than 80% of elderly people do not read or write.24 The mini
mental state examination (MMSE) has been translated into many languages, but its use
might be limited even as an initial screening tool. Independent back translations and
consistent informant assessments are therefore mandated. Neuropsychological test batteries
with components relatively free of cultural and linguistic factors (eg, verbal tests of delayed
recall and of language) have been developed,25 but experience suggests that assessments
must be consistent with the culture and language of the population under study, and local
normative data for test performance need to be compiled.26
To achieve universal standardisation and to chart the epidemiological transition and its
effect on older people, the 10/66 Dementia Research Group centres have initiated evidence-
based procedures for use in different catchment areas worldwide.27 These include cross-
culturally validated assessments for dementia subtype diagnosis, other mental and physical
health diagnoses, anthropometry, demographics, non-communicable disease risk factors,
disability and functioning, health-service utilisation, care arrangements, and caregiver strain.
Nested within the population-based studies is a randomised controlled trial of caregiver
intervention for people with dementia and their families.27 The surveys include
ascertainment of other mental disorders, vascular disease, chronic obstructive pulmonary
disease, and arthritis.27 Documentation of specific functional decline can be a challenge,
because in some cultures, elderly individuals might have a restricted range of activities
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available to them, or family members might take over these activities. However, a history of
cognitive decline can generally be combined with psychometric testing to support the
diagnosis. Determination of the correct age of individuals who do not possess formal
documentation of birth is another factor that could hamper comparisons, although methods
on how accuracy might be achieved have been recognised.28,29
Dementia prevalence and incidence
Since the Delphi study projections,2 several large-scale dementia prevalence studies have
been done.30–39 Dementia prevalence estimates vary widely within developing countries
(table 1). This variation might indicate differences in population age structure, genetics, and
lifestyle, but could also be due to difficulty in standardising dementia assessment and
reduced survival after diagnosis.15 The mean age-adjusted prevalence estimate for dementia
among people aged 65 years and older living in developing countries, derived from data
published within the past 10 years, was calculated to be 5.3% (95% CI 3.9–6.5; table 1).
This estimate was obtained by determining the original sample sizes and numbers of
dementia cases reported to be 65 years and older in individual studies per country, and re-
calculating mean estimates and variation by use of SPSS 15.0, according to the method by
Yang.59
Surprisingly, countries in Latin America, such as Venezuela and Argentina, bear a higher
burden of over 5% prevalence of dementia (figure). By contrast, a systematic analysis of six
Indian studies suggests low prevalence (2–3%) of all dementias, with marginally fewer cases
in urban compared with rural areas and in the northern versus southern states.33 Pooled
analysis of 25 Chinese studies by Dong and colleagues,30 comprising a total population of
more than 76 000, suggested that the overall prevalence of dementia was 3.1%, indicating a
significant rise from 1980 to 2004. However, a recent survey of over 34 807 Han Chinese
residents aged at least 55 years in 79 rural and 58 urban communities of four distant areas
reported a crude prevalence estimate of 5.0%, and 6.8% after adjustment for negative
screening.31 Higher prevalence was apparent in northern regions compared with the south,
but no difference was evident among urban and rural Chinese residents.7 In the Upper Assiut
region along the Nile, age-adjusted dementia prevalence in people aged 65 years and older
was 5.9%.51 In the Yoruba (Niger-Kordofanian people) of Nigeria, dementia prevalence was
low (2.3%) compared with an African American population in Indiana, USA (8.2%).52
Among Arabs living in Wadi Ara, a community south of Haifa in Israel, the crude
prevalence estimate for all dementias was 21% in those aged over 60 years.50,74
Consanguinity among families was suggested as a reason for this high prevalence.74,75
Studies from developing countries in Eastern Europe have assessed some risk factors, but
prevalence or incidence data in these communities are unknown.62
The variations in prevalence within developing countries seem close to those found in the
recently completed 10/66 survey of 14 960 residents aged over 65 years in 11 sites in seven
low-income and middle-income countries (China, India, Cuba, Dominican Republic,
Venezuela, Mexico, and Peru).20 Prevalence of dementia according to the Diagnostic and
Statistical Manual of Mental Disorders (4th edition) varied widely, from less than 1% in the
least developed countries, such as India and rural Peru, to 6.4% in Cuba. The 10/66 study
also found that informants in the least developed countries were less likely to report
cognitive decline and social impairment,20 suggesting possible underestimation of
prevalence estimates in some locations.
Few incidence estimates are available to substantiate prevalence figures for those aged 65
years and older. Compared with developed countries, relatively lower annual incidence
estimates of 1–2% are reported in certain countries, such as Brazil, Nigeria, India, and
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Taiwan.41,46,63,76 In a Brazilian community, incidence was determined to be 13.8 per 1000
person-years.76 In a comparative study, the Yoruba in Nigeria were found to be half as
likely to develop dementia as African Americans in Indiana, USA; age-standardised annual
incidence was 1.4% in the Yoruba versus 3.2% in African Americans.63 Among residents
aged 60 years and older in Beijing, China, an incidence of 0.9% was determined at follow-
up versus the original prevalence of 2.5%. AD was the most common type of dementia in
both prevalent and incident cases.77
Subtypes of dementia
Alzheimer's disease
Late-onset AD is the most common subtype of age-related dementia, even in developing
countries; 60% of all cases of dementia fulfilled the US National Institute of Neurological
and Communicative Disorders and Stroke and the Alzheimer's Disease and Related
Disorders Association (NINCDS–ADRDA) criteria.78 Total population projections suggest
that 3.1 million people in China could have AD. Although unusually high prevalence was
apparent in some countries, the mean AD prevalence was estimated to be 3.4% (95% CI
1.6–5.0), which is slightly lower than in developed countries. Age-adjusted low prevalence
(<1.5%) was reported in sub-Saharan Africa (Nigeria) and India (table 1). The mean
estimate was obtained by retrieving the original sample sizes and numbers of probable AD
cases in individual studies per country and re-calculating the rate and variation by use of
SPSS 15.0, according to the method by Yang.59 Autopsy studies done in some developing
countries have confirmed that the neuropathological changes associated with AD are
qualitatively similar to those in patients in developed countries;79–81 however, more work is
needed, particularly given that reported AD cases could also have cerebrovascular changes.
30,31,33
Consistent with the prevalence estimates, the incidence of AD for those aged 65 years and
older was 7.7 per 1000 person-years in Brazil,76 and 3.24 per 1000 person-years in India.82
The annual incidence of AD in the Yoruba was determined to be 1.2%, substantially lower
than the incidence of 2.5% in African Americans from Indiana.63
Vascular dementia
Vascular dementia (VaD) is recognised as the second most prevalent type of dementia.
Neuroimaging is not routinely available in developing countries, which influences the
accuracy of VaD detection and the confirmation of cases of mixed dementia. Analysis of
data from 12 centres30–36,39,43,44 for which imaging findings were available indicates that
26% of cases of dementia fulfilled the US National Institute of Neurological Disorders and
Stroke and Association Internationale pour la Recherché et l'Enseignement en
Neurosciences (NINDS–AIREN) criteria for VaD.83 The mean estimate was obtained by
determining the screened samples and numbers of reported VaD cases in individual studies
per country and calculating the mean and variation in the same way as for AD prevalence.
Prevalence estimates of VaD in developing countries range from 0.6% to 2.1% in those aged
over 65 years (table 1). A third of 4.5 million Chinese patients with dementia are predicted
to have VaD.31 With the exception of some Latin American and Asian countries,84 VaD
prevalence in developing countries seems to be low. VaD might be more common among
the Chinese and Malays, whereas AD is common in Indians and Eurasians.85 Subcortical
VaD caused by small-artery disease,6 associated with hypertensive disease, seems to be a
common (73%) cause of VaD.64 In several countries in Asia and Latin America, up to 10%
of dementia cases are diagnosed with mixed dementia.30,40 Up to 30% of Chinese people in
urban areas develop post-stroke cognitive impairment or delayed dementia after stroke.86–88
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However, the prevalence of vascular cognitive impairment that involves all domains of
cognitive function and causes of vascular injury is likely to be greater than that of VaD.89
Other subtypes of dementia
Prevalence data on other types of neurodegenerative dementia are limited. Single case
reports and dementia prevalence studies do record causes of dementia other than AD (table
1). The first autopsy-confirmed case report of dementia with Lewy bodies in sub-Saharan
Africa was reported in a Nigerian patient.90 Cases of dementia with Lewy bodies and
Parkinson's disease with dementia have been reported in India,91 Sri Lanka,49 Taiwan,92 and
China.30,93 Frontotemporal lobar degeneration, which involves a range of disorders
associated with and without microtubule-associated Tau protein accumulation, does exist in
developing countries but has rarely been described.30,92,94 Several cases of primary
progressive aphasia with slow progressive deterioration of linguistic processes have been
reported in Brazil.95 The Chamorros of Guam are affected by amyotrophic lateral sclerosis
(ALS) and Parkinson's dementia complex (PDC), both of which are associated with
pathological changes that resemble the neurofibrillary tangles found in AD.96 However,
Guam has experienced rapid modernisation since World War II, and the incidence of ALS
and PDC has declined.65 Recent studies indicate that the prevalence of dementia is
approximately 12% among Chamorros aged 65 years or over (8.8% Guam dementia
[clinically resembles AD], 1.5% PDC, and 1.3% VaD). Prion diseases, including sporadic,
dominantly inherited, or transmitted cases of Creutzfeldt-Jakob disease, have also been
described.66 The 129M susceptibility allele of the prion protein gene is found at high
frequencies in Eurasian populations.67
Familial forms of dementia
Worldwide prevalence of early-onset dementias, generally defined as occurring before 65
years of age, is expected to be much higher than the global prevalence of early-onset AD at
approximately 5.3 per 100 000 population.97 Most monogenic and complex disorders,
including familial AD, Parkinson's disease with dementia, frontotemporal lobar
degeneration, Huntington's disease, and small-vessel diseases of the brain, have been
described in developing countries, but their frequencies are unknown (figure). Indigenous
African and Asian families have been found with early-onset (33–45 years) AD caused by
mutations in the amyloid precursor protein and presenilin genes.68,92,98,99 In Medellin,
Colombia, the E280A mutation in the presenilin 1 gene (PSEN1) causes severe AD in a
large kindred.100 Over 200 families with early-onset AD have also been identified among
Caribbean Hispanics originating from the Dominican Republic and Puerto Rico.101 In 10%
of these families, at least one family member had onset of dementia before the age of 55
years and almost half showed an association with a previously unreported presenilin
mutation.101
Many families with early-onset VaD of small-vessel-disease type, in the form of cerebral
autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy
(CADASIL),89 have been described in Asia, Africa, and Latin America.69,70,102 The
trinucleotide repeat (CAG, GCC expansion) diseases, of which Huntington's disease is an
example, are an important cause of disability and dementia in sub-Saharan Africa,103 Asia,
92,104 and Latin America.105 In Maracaibo, Venezuela, the estimated prevalence of
Huntington's disease in the state of Zulia is about 720 in 100 000 inhabitants, compared with
5–10 per 100 000 reported worldwide.71 Of note, environmental factors have been shown to
influence the phenotypic expression of these dominant genes.72,106
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Behavioural and psychological symptoms of dementia
Behavioural and psychological symptoms of dementia (BPSDs) are common among people
with dementia in developing countries, although there seem to be marked regional variants.
22,107 Several factors, including methods of reporting and cultural taboos, might account for
the variations. However, at least one BPSD was reported in 70% of participants from 17
developing countries, and at least one case-level AGECAT psychiatric syndrome was shown
by nearly half of those with dementia.27 Depression syndromes are most commonly
followed by anxiety neurosis and schizophreniform or paranoid psychosis. Almost 80% of
patients with AD in a Brazilian study had one or more BSPDs.108 Apathy was present in
more than half (53%), followed by depression (38%), sleep alterations (38%), and anxiety
(25%), whereas the most frequent neuropsychiatric symptoms in the cognitively impaired
(but not demented) group were anxiety and sleep alterations, followed by depression.108 In
India, patients with AD rather than VaD have significantly more delusions, hallucinations,
anxieties, phobias, and caregiver distress with longitudinal patterns similar to those reported
in developed countries.91 Poor cognitive performance was associated with significantly
higher rates of depression in the Yoruba.109 Despite substantial socioeconomic and cultural
differences between the Yoruba and African Americans, prevalence estimates of both mild
and severe depression are generally similar in the two population samples.109 Although
patterns of behavioural disturbances might vary,108,110 BPSDs seem to be common in
developing and developed countries.
Early stages of dementia and mild cognitive impairment
The transition or prodromal stage between normal ageing and dementia or mild cognitive
impairment (MCI) is a heterogeneous entity. Diagnostic criteria and standardisation of MCI
are evolving, which makes direct comparisons among studies more difficult, possibly due to
the stronger influence of illiteracy and socioeconomic factors, than in similar studies when
dementia is diagnosed. Patients and families in developing countries are also less likely to
admit or report cognitive difficulties because of prevailing cultural attitudes; identification
of MCI in these countries therefore requires the presence of additional factors, such as
infection and vascular comorbidites and poor nutrition. A small number of studies suggest
that conversion rates of MCI or cognitive impairment with no dementia seem to be low in
developing countries,111,112 but they report similar prevalences of impairment to those in
developed countries. An Indian cross-sectional study reported that, in individuals aged 50
years and older, overall prevalence of MCI was 14.9% (95% CI 12.2–18.0) and that
multiple-domain MCI was the most prevalent (8.85%) and was associated with increasing
age, hypertension, and diabetes mellitus.113 In Brazil, prevalence of cognitive functional
impairment was 16–19%.114 Higher age, low education, epilepsy, and depression were
associated with increased risk, as were being female, widowhood, low social class, and head
trauma. Stroke and diabetes were also associated with MCI within communities in Brazil,
Puerto Rico, and Malaysia.114,115
Risk factors for dementia
Age and sex
Exposure early in life to deleterious conditions related to poverty, including infectious
diseases, malnutrition, and prenatal stress, might influence the ageing process and reduce
longevity for people in developing countries.116,117 Despite these realities, increasing age is
the most consistent risk factor for dementia worldwide (table 2). Age was also a strong risk
factor,30,51 with dementia prevalence of 2–11%, in those aged under 65 years. Nearly all
studies in Latin America, Africa, and Asia confirm that women are marginally more likely
to develop dementia and AD, particularly in very old age,76 on the basis of the greater
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expected numbers of ageing women,1 whereas VaD was slightly more prevalent in men
(table 2).
Early-life negative events and physical attributes
Recent studies suggest that various genetic and environmental factors, including early-life
brain development, body growth, socioeconomic conditions, environmental enrichment,
head injury, and cognitive reserve, are likely to contribute to dementia risk.120,127 These
factors have not been specifically investigated, but people in developing countries have a
greater likelihood of early-life negative risks. Life expectancy at birth is much lower than in
developed countries because of higher infant and maternal mortality and greater prevalence
of infectious diseases. However, differences between developing and developed countries
are substantially reduced in those who have reached the age of 65 years.128 In addition,
older people in an area with high early-life mortality are not necessarily protected from
dementia. In fact, such individuals continue to be at higher risk of death.129 Nevertheless,
physical characteristics, such as leg length and head circumference, might be markers of
early-life stressors,118,119,130 which result in reduced cognitive reserve. Significant negative
early-life events might also increase the risk of AD among survivors.131
Literacy and education
On the one hand, illiteracy or low educational achievement has been shown to be a robust
risk factor for dementia.120 On the other hand, intellectually stimulating, socially engaging,
or physical activities might lower the risk of dementia.121 The situation is not different in
developing countries, where surveys have consistently identified low education as a risk
factor for dementia (table 2).85 However, in some communities, level of education, indexed
by years of primary schooling, might not necessarily contribute to low prevalence.18 Low
literacy is often linked to poverty or lower socioeconomic status, which is also associated
with poorer health, lower access to health care, and increased risk of dementia (table 2).
35,76,132
Genetic association studies and risk genes
Several groups in Asia and Latin America have done genetic association studies, spanning
more than 127 polymorphisms across at least 69 different putative AD susceptibility genes.
133 Genetic traits with autosomal recessive features are being explored in communities with
high consanguinity. For example, studies in Wadi Ara have shown clustering of AD in
families, and association with a new haplotype of the angiotensin-converting enzyme.134,135
The association of AD with at least two genes, apolipoprotein E (APOE) and neuronal
sortilin-related receptor (SORL1),133,136,137 seems to be affected by ethnicity, age, sex,
medical history, and geographical location. The APOE ε4 allele does not increase risk in
sub-Saharan Africans and is only weakly associated with AD in Caribbean Hispanics and
African Caribbean people of Jamaican origin.101,136,138 APOE ε4 is a risk factor for AD
among women but not men in Venezuela.139 However, frequencies of the APOE ε4 allele
are reported to be relatively increased in healthy Africans and some non-Africans: for
example, 14–41% in indigenous people from Central African Republic, East Africa,
Southern Africa, Malaysia, Australia, and Papua New Guinea,122,123,140 compared with 8–
12% in Caucasians and Japanese.136 By contrast, certain groups have low frequencies of the
APOE ε4 allele: 3–4% in the Wadi Ara Arabs in Israel, Oman, and Algeria,134 and 7% in
North Indians and Taiwanese people.92,141
Comparative analysis showed that the APOE ε4 allele was a risk factor for AD in African
Americans, but not in Yoruba Nigerians,124,142 or in population samples from the Vihiga
and Nyeri districts of Kenya,29 or Kingston, Jamaica.143 There was also a lack of association
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of APOE genotypes with risk for dementia after adjusting for sex, age at diagnosis, and
education,68,122,124 and in communities with high consangunity.134
Early-onset familial AD in developed countries has not been reported to be modified by the
APOE ε4 allele. However, patients with early-onset AD carrying the APOE ε4 allele in the
Colombian kindred with the E280A presenilin mutation were twice as likely to develop
disease at an earlier age than those without the APOE ε4 allele.144 Low education and rural
residence also influenced the age of onset in these patients.144 The APOE ε4 allele was
strongly associated with late-onset familial AD among Caribbean Hispanics from the
Dominican Republic and Puerto Rico,101 but not in Guamanians with dementia.65 The risk
of ALS, PDC, and AD in Guam seems to be associated with genetic variants within the Tau
gene, one of which increases the risk for progressive supranuclear palsy.145
The SORL1 gene, which might influence homoeostasis of the amyloid precursor protein, is
thought to be the second most important gene to modify late-onset AD in multiple and
ethnically diverse populations.137 Association of risk with this gene was found in Wadi Ara
Arabs, among whom there is high consanguinity, as well as in Caribbean Hispanics137 and
Han Chinese.146 Allelic heterogeneity in SORL1 is suggested by the novel single-nucleotide
polymorphisms that have been found to be associated with the gene.133
Stroke and vascular disease risk factors
Stroke is an increasing burden in developing countries,147,148 and a major cause of mortality
and long-term disability.149 Accumulating evidence suggests that stroke injury and vascular
factors increase risk for AD and other dementias.10,89,150–155 Vascular factors, such as
hypertension,9 dyslipidaemia,156,157 hyperinsulinaemia and type 2 diabetes,158,159 obesity,
160 subclinical atherosclerosis,161 and arrhythmias,162 are associated with greater risk of
cognitive impairment and dementia. Studies in Latin America also show that metabolic
syndrome doubles the risk of cognitive impairment,163 and is significantly associated with
functional dependence, depression, and low quality of life.164 Factors that decrease vascular
function, such as tobacco use, which is common in countries such as China,165 might further
influence cognition in old age.
The shift from infectious diseases to non-communicable but modifiable chronic disorders
has resulted from gradual adoption of a Western lifestyle that includes excessive caloric
intake, unhealthy diet, and decreased physical activity.160,165–170 This trend is expected to
contribute to the global burden of AD.171,172 Vascular disease-controlling medications, such
as antihypertensives and statins, might not be protective.173,174 The most cost-effective way
to prevent dementia might be through dietary or lifestyle interventions in communities at
variable risk of cardiovascular disease,175 such as the Yoruba,176 northern Indians,177
Venezuelans,178 and Wadi Ara Arabs.179
Dietary factors
Studies examining nutritional risk, which often rely on self-reports, are fraught with
difficulties and should be cautiously interpreted. Observational data suggest that the low risk
of dementia in some developing countries can be attributed to the type of diet.180 Diets rich
in fruits, vegetables, and fibre improve human well-being and significantly reduce
development of the pathological processes that are characteristic of neurodegenerative
disorders.181 Chinese studies suggest that regular tea drinking might be protective against
AD.182 The low incidence of dementia in the Yoruba Nigerians is consistent with their
traditional low calorie and low fat diet consisting of grains, yam tubers (Dioscorea
rotundata), vegetables, and some fish.176 Among Indonesians, there is a 30% lower risk of
impairment with higher consumption of mucuna tempe,73 which has a high fibre content.183
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By contrast, eating tofu has been associated with worsening memory, independent of age,
sex, and education, among Indonesians,73 which concurs with the association of tofu
consumption in midlife and cognitive impairment and brain atrophy in elderly Japanese
Americans.184 Salivary phytooestrogens (genistein and daidizein) are associated with a
higher risk of dementia, particularly in Javanese people aged over 68 years.73 The
interaction between ageing and staple diets containing potential toxins might explain the
dementia prevalence in certain locations such as Guam, where preparing or eating cycad
fruit during young adulthood is associated with late-life dementia and PDC.145
Use of herbs and medicinal plants for dementia
Developing countries tend to retain traditional herbal medical practices and thus offer an
invaluable resource for new anti-dementia therapies.185 However, the usefulness of such a
resource relies on documented evidence of the effects. One of the largest long-term
controlled clinical trials in progress on dementia prevention is based on the Asian traditional
tree medicine Gingko biloba.186 Preliminary data have indicated significant effects on
dementia progression,187 but the most recent Cochrane analysis concluded that evidence of
predictable and clinically significant benefit of G biloba and standardised extract (EGb 761)
for people with dementia is inconsistent and unconvincing.188 Huperzine A, originally
isolated from Huperzia serrata, a type of moss used in traditional Chinese medicine (also
known as qiang ceng ta),189 has been marketed in China as a new drug for AD treatment,
and its derivative, ZT-1, is being developed as a new anti-AD drug.190,191 A plethora of
pharmacognostic practices, including those for cognitive care, still exist in countries such as
Africa, South America, India, and in other aboriginal cultures.185 Other relevant
phytotherapeutics from developing countries, including combinations of traditional Chinese
medicinal herbs (yi-gan san and ba wei di huang wan), sage (Salvia officinalis and Salvia
lavandulaefolia), and lemon balm (Melissa officinalis), which have shown positive benefits
on behavioural symptoms and cognition, need to be explored in wider studies.192,193
Several species of medicinal plants have activities in vitro or in vivo that are relevant to
dementia (eg, anti-cholinesterase, anti-amyloid, anti-inflammatory, anti-oxidant,
neuroprotective, and memory enhancing). The most frequently reported are blueberry,
cannabis, club moss, curcumin, garlic, ginseng, green tea, pomegranate, and rhubarb.
170,181,194,195 The dementia drug rivastigmine is a synthetic chemical analogue of
physostigmine (from the Calabar bean, Physostigma venenosum), and galantamine is the
main alkaloid in daffodil and snowdrop bulbs.196 Initiatives thus need to continue to protect,
assess, and standardise traditional herbal medicines used in developing countries.
Mortality and dementia
Dementia modifies survival and increases the risk of death. A study among Shanghai
residents indicated that the mortality risk ratios for AD and VaD, particularly in those over
75 years of age, were similar to the mortality risk ratio for cancer.125 In another Chinese
study, the risk for death in patients with dementia was reported to be three times higher than
in the whole cohort, although not related to a specific cause.84 In Brazilians, dementia was
determined to be the most significant predictor of death, followed by age, history of stroke,
complaints of visual impairment, heart failure, and severe arterial hypertension.197 In
Ballabgarh, India, the median survival time after onset of dementia symptoms was
determined to be 3.3 years for patients with dementia and 2.7 years for patients with AD
compared with 5.0–9.3 years in developed countries.46 Dementia was also associated with
increased mortality in Nigerians and African Americans (relative risk ratio, compared with
the population studies, was 2.83 versus 2.05).198,199
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Costs of dementia
Current projections indicate that the burden of disease, expressed as WHO-designated
disability-adjusted life-years (DALYs), is unequally distributed between middle-income and
low-income countries (table 3).16,200 However, if dementia prevalence in developing
countries is assumed to increase substantially due to demographic transition, the DALYs per
number of patients with dementia who are 65 years and older are similar between regions.5
To estimate the total costs, we modelled the societal worldwide costs as well as region-
specific and country-specific costs by combining prevalence estimates,5 country-specific,
and region-specific data on gross domestic product per person, and average wage with
results from previously published cost-of-illness studies in several key countries from which
detailed data about direct costs and informal care costs were available.201 From this model,
total costs of dementia in developing countries are estimated to be US$72.6 billion yearly
(table 3). By use of the lower Delphi estimates,2 costs for Africa would be US$2.9 billion.
201 Cost estimates do not provide any information about the cost distribution among those
who actually pay or how large a proportion of the total resources are required for a particular
disorder.202 In developed countries, long-term institutional care constitutes the main cost,
203,204 whereas in developing countries, informal care, usually at home,205 is invariably the
only method of care.206,207
The cost model estimates that approximately 75% of the global costs occurred in middle-
income countries, where 46% of patients with dementia worldwide reside,201 but informal
care costs, which are increasing in developing countries,13,208 were proportionally greater
(1.0 of 1.8 billion or 56% of total) in the least developed countries.201 For example, in
Argentina and Brazil,209,210 the expenses (medical and non-medical) borne by families of
people with dementia were considered to be very high. Similarly, in China, non-medical
costs increased with severity of cognitive decline and increases in BPSDs, and daily 24-hour
care was needed for those with a MMSE score below 11 and BPSDs.211 In Turkey, informal
care was estimated (by use of a replacement cost approach) to be the major cost driver,
although the amount of informal care time was lower than in other studies.206 The
dominance of informal care was evident in South Korea, where these costs constituted 55%
of societal costs,212 but in India, the amount of informal care was similar to that in middle-
income countries.213 By contrast, the costs of home care (including informal care) with
nursing care in Taiwan were less than for institutional care, particularly for patients with
severe dementia if a replacement cost approach was used.214,215 The weakness of such
projections is that they rely on extrapolation of data from middle-income countries,216 and
require information about true prevalence, and the conceptualisation, quantification, and
actual costs of informal care.201 Definitions of care activities, particularly in terms of
instrumental activities of daily living and supervision versus normal family activities, also
pose difficulties in the estimations of overall cost.
Dementia awareness, care, and services
Understanding the burden and costs of dementia is crucial to guide future health care and
socioeconomic policy.27 Policymakers need evidence to prioritise and plan appropriately for
the rapidly growing numbers of older people with dementia and other chronic diseases. Low
public awareness, under-diagnosis, and under-treatment could be addressed by national
mobilisation strategies to increase awareness and specialised training for heath professionals
and authorities through mass media, scientific reports, and special activities, and by the
setting up of open clinics in communities. For example, through such efforts, the mean
proportion of patients with AD in China treated with acetylcholinesterase inhibitors and
memantine increased from 12.1% (range 0.2–29.1%) in 2001 to 19.6% (range 2.3–41.1%) in
Kalaria et al. Page 11
Lancet Neurol. Author manuscript; available in PMC 2010 April 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2007.217 The variation among the Chinese districts mainly depended on the levels of
economic development and medical insurance cover.7
Social protection is hard to define, but is a major concern in most developing countries. This
might be complicated by a lack of carers due to urban and economic migration, conflict, and
HIV/AIDS. The circumstances of those with dementia in each centre of the 10/66 study,
surveyed by use of an adapted version of the Client Service Inventory Report,27 highlight
the vulnerabilities of dependent older people living in these regions.218 For people with
dementia, the state does not provide long-term care; consequently, the family, particularly
the patients' offspring, plays a vital part. An estimate of the worldwide costs of dementia
used an average of 1.6 hours of informal personal care per day for all people with dementia.
201 However, this figure is exceeded in most 10/66 study centres. In all Latin American
centres other than Mexico, a sixth to a quarter of people with dementia have no children
locally available to provide care. Even in rural China and in India, 5–10% lack this
fundamental support.218 Children can provide food, shelter, personal care, and income for
their parents through cash transfers (particularly important in India, Dominican Republic,
rural Peru, Mexico, and China because of very low pension coverage). In all 10/66 centres,
living with children is the norm, and three-generation households (including children under
16 years) are common.205 Nevertheless, around a fifth of people with dementia (10–37% by
centre) live alone or with a spouse only, and hence can be considered vulnerable.207,218
Current research indicates that a worryingly high proportion of people with dementia lack
the basic necessities for life (ie, food), particularly in parts of Latin America, and in India,
where social protection is most insecure.4,205,207,209,210,218,219
International agreements, plans, and policy guidelines have called for an end to age
discrimination and a focus on reducing disadvantage linked to poverty and the consequences
of ill health.1 Ensuring social protection, allowing access to good quality age-appropriate
health care, and addressing the problem of disability are key concerns. Thus, levels of
caregiver strain, including that contributed by behavioural disturbances and stress, are as
high as in developed countries despite extended family networks and home care.207
Moreover, dependency is strongly linked to poverty, and imposes additional economic strain
on families.207 The Ibadan project in Nigeria has advocated periodic home visits, and
empowerment of caregivers through regular meetings to make caring for individuals with
dementia easier and more adaptable.220
Conclusions
The prevalence of dementia, particularly that of AD, is increasing in the developing
countries of Asia and Latin America. However, reliable age-adjusted estimates indicate a
low prevalence of dementia in India and sub-Saharan Africa. Difficulties in definition,
ascertainment of decline in intellectual ability, and assessment of patients mean that meagre
information on MCI is available in developing countries.20 Illiteracy and depressive illness
remain strong risks for dementia. Further research is needed to examine why the APOE ε4
allele does not seem to influence AD progression in sub-Saharan Africa. Increasing
frequency of vascular disease and global trends in modernisation will add to the burden of
AD within developing countries. Harmonisation of screening methods worldwide could help
to define risks and to devise novel approaches for dementia prevention. The impact of
dementia in developing countries deserves further epidemiological and implementation
research to enable early detection, widespread adequate treatment, and caregiver support.
Such efforts will no doubt promote greater awareness, refine the policy agenda, and lead to a
call for concerted action.
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Search strategy and selection criteria
First-hand information on cognitive screening and several relevant references were
provided by the World Federation of Neurology Dementia Research Group members and
co-authors. A systematic literature search of PubMed and Medline was also done with
combinations of search terms, including “developing countries” and “dementia”, with
topic headings including “Alzheimer's disease”, “prevalence”, “incidence”, “cognitive
impairment”, “mortality”, “risk factors”, “vascular dementia”, “Asia”, “Africa”, “Latin
America”, “care”, and “costs”. PubMed was searched for relevant articles in any
language (all understood by co-authors) until May, 2008. Searches were also done in the
Cochrane database, EMBASE, Dare, NHS-EED, HTA, Applied Social Sciences Index
and Abstracts, Social Services Abstracts, Sociological Abstracts, PsycINFO, and Social
Sciences Citation Index with combinations of similar search terms. Some publications,
particularly conference proceedings, were found through Google searches. The
bibliography was derived from a total of 520 articles that were screened for relevance to
this Review. The full list of search terms is available from the authors on request.
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Figure. Sporadic and familial dementias in developing countries
Red-shaded countries have prevalence or incidence estimates of all dementias that have been
determined to be similar (>5%) to those in developed countries (grey-shaded countries).
Blue-shaded countries have significantly lower prevalence (<3%) of dementia. Sample sizes
for the estimates in the various studies were between 700 and 3200 individuals. Green-
shaded areas show countries where there are published cases of dementia or subtypes (AD
or VaD), where risk factors have been examined but prevalence or incidence are unknown.
Reliable information was not available for countries without shading. Red spots show
locations of families with neurodegenerative and vascular disorders causing dementia
including AD, Parkinson's disease, Lewy body disease, frontotemporal lobar degeneration,
Huntington's disease, amyotrophic lateral sclerosis, and CADASIL. Information on
dementia prevalence and types was derived from many sources.22,29,31,35,37–39,41,45,46,49–
52,58,62–73
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Table 2
Comparison of risk factors for dementia, AD, and VaD, in developed and developing
world regions
Developed regions
(North America,
Europe, Japan)
Asia (China, Guam,
India, South Korea,
Taiwan*)
Africa (Egypt,
Nigeria, Kenya,
South Africa)
Latin America
(Argentina, Brazil,
Venezuela)
Increasing age Positive Positive Positive Positive
Female sex Positive Positive Unclear Unclear
Family history Positive Positive .. Positive
Head injury Positive .. .. Positive
Genes (APOE ε4 allele) Positive Positive No risk Unclear
Illiteracy or lack of education Positive Positive Positive Positive
MCI or cognitive impairment without
dementia
Positive Positive .. Positive
Urban living Unclear Unclear Negative Positive
Low socioeconomic status or poverty Unclear Positive .. Positive
Occupation as housewife Negative Positive Unclear Positive
Depressive illness Positive Positive Positive Positive
Vascular disease† Positive Positive Positive Unclear
Low fibre diet Unclear Positive Positive ..
Smoking Positive Positive .. Unclear
*
In a 3-year incidence study, lower education, history of consistent unemployment, limited physical activity, and stroke history were identified as
risk factors for dementia.84
†
Hypertension and diabetes were the most common risk factors associated with cases of AD and VaD. Studies in South Koreans and Jamaican
Caribbeans established that smaller head circumference and shorter leg length were risk factors for dementia.118,119 Summary compiled from
previously published studies.15,18,19,29–31,33–35,37–39,41,42,45–52,54,56,62,65,73,76,101,109,113,115,120–126 MCI=Mild cognitive
impairment. ..=not determined.
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